Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

Registry ID
2026-526828-41-00
Source registry
CTIS
Status
Authorised
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Enrollment
150
Last update
2026-08-14

Conditions

Primary outcomes

The primary endpoint is the difference in mean change of total erosion volume (mm3) of target joints (II, III, IV, V distal and proximal interphalangeal joints and II, III, IV, V metacarpal phalangeal joints) assessed with high resolution peripheral quantitative computed tomography (HRpQCT) using standardized approach between baseline (V1) and 12 months after baseline (V4)

Locations

Related clinical trials

View on source registry